Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weekly treatment tested to protect hemophilia Patients' joints

NCT ID NCT06752850

Summary

This study is checking if a weekly preventative treatment (efanesoctocog alfa) can improve the health of joints already affected by swelling (synovial hypertrophy) and prevent new joint bleeds in people with moderate or severe hemophilia A. About 37 participants aged 12 and older will receive the weekly treatment for 12 months. Doctors will use ultrasound and MRI scans to closely monitor changes in the participants' joints over the year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Sobi Investigational Site

    Milan, Italy

  • Sobi Investigational Site

    Naples, Italy

  • Sobi Investigational Site

    Rozzano, Italy

  • Sobi Investigational Site

    Oslo, Norway

  • Sobi Investigational Site

    Barcelona, Spain

  • Sobi Investigational Site

    Madrid, Spain

  • Sobi Investigational Site

    Seville, Spain

  • Sobi Investigational Site

    Valencia, Spain

  • Sobi Investigational Site

    Gothenburg, Sweden

  • Sobi Investigational Site

    Malmo, Sweden

Conditions

Explore the condition pages connected to this study.